Welcome to our dedicated page for Polyrizon SEC filings (Ticker: PLRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd. reports that shareholders approved all proposals presented at the annual general meeting held on July 13, 2026. These approvals were made by the requisite majorities under Israeli Companies Law and the company’s amended and restated articles of association.
A key outcome is the adoption of an amended Compensation Policy for executive officers and directors, which will serve as the company’s compensation framework for three years from July 13, 2026. The policy ties executive pay to Polyrizon’s business and financial long-term goals and allows for base salary, benefits, cash bonuses, equity-based compensation, and various retirement and termination arrangements.
The policy permits up to 12 months’ prior notice of termination for the CEO and chairperson and six months for other executive officers, plus a possible additional adjustment period of up to six months, during which all compensation elements and equity vesting may continue. It also allows non-compete grants and other non-statutory payments, with total non-statutory amounts capped at 24 times an executive’s monthly base salary. Directors and executive officers may also benefit from exculpation, indemnification, and insurance to the fullest extent permitted by law. The 6-K and the full Compensation Policy are incorporated by reference into Polyrizon’s existing Form S-8 and Form F-3 registration statements.
Polyrizon Ltd. reported that its NASARIX/Allergy Blocker nasal spray achieved successful results in a comprehensive biocompatibility evaluation program. All required biological safety tests met their predefined acceptance criteria, supporting the product’s safety profile for intranasal use.
The program followed internationally recognized standards, including the ISO 10993 series, FDA guidance and European regulatory requirements, and assessed biological endpoints, long-term systemic toxicity and toxicological risk based on final product configuration and materials. These non-clinical results are presented as a key milestone toward advancing the device to its first-in-human clinical trial and potential commercialization as a drug-free nasal barrier for managing seasonal allergic rhinitis.
Polyrizon Ltd. reports that it has received central Institutional Review Board (IRB) approval from BRANY to begin its first human clinical trial of NASARIX™, a nasal spray designed to block airborne allergens in people with seasonal allergic rhinitis.
The approved study will compare NASARIX against a saline spray to evaluate efficacy, safety and tolerability, using a master protocol, informed consent documents, quality-of-life assessments and electronic diary tools that have all been cleared by the IRB. The central approval, granted on June 18, 2026, covers the study’s master file through June 17, 2027, while individual clinical sites must still obtain their own site-specific IRB approvals before activating sites and enrolling patients.
Polyrizon Ltd., a development-stage biotech company focused on intranasal hydrogels, reported that a U.S. patent application covering its Trap & Target™ mucoadhesive nasal drug delivery platform has been published as patent application No. US 2024/0358741 A1.
The application describes biocompatible mucoadhesive polymers that form a durable film on mucosal surfaces to enhance retention, absorption, and sprayability for nasal and oral formulations. Potential uses include sprays, gels, inhalation products, and localized or systemic delivery of drugs such as anti-inflammatories, vaccines, biologics, and other active ingredients.
Polyrizon positions this Trap & Target technology alongside its existing Capture and Contain™ hydrogel “biological mask” platform, both aimed at improving nasal barrier protection and drug delivery. The company cautions that there is no assurance any patent will ultimately issue from the pending application.
Polyrizon Ltd. reports a key development for its NASARIX™ (PL-14) Allergy Blocker program. The company has signed agreements with a leading European university medical center and a specialized contract research organization to run a human performance and characterization study.
The single-site study in healthy participants will measure how long the intranasal NASARIX™ hydrogel remains in the nasal cavity, helping estimate the duration of its protective barrier function against allergens. It will follow Good Clinical Practice and European medical device regulations and is intended to support Polyrizon’s broader verification and validation program and planned regulatory submissions, including to the U.S. FDA.
Polyrizon Ltd. announced that the European Patent Office has completed technical preparations for publication of its European patent application EP 4751737 for mucoadhesive polymers used in nasal drug delivery. The application covers the company’s proprietary Trap & Target™ technology platform, designed to improve retention and absorption of drugs in the nasal cavity.
The publication is described as an important step in Polyrizon’s strategy to build its intellectual property portfolio and support future pharmaceutical collaborations in nasal drug delivery. The patent application remains under European examination, and any eventual grant could offer protection in multiple European markets but is not assured.
Polyrizon Ltd. has called its Annual General Meeting for July 13, 2026 in Raanana, Israel. Shareholders of record on June 15, 2026, when 2,083,979 ordinary shares were outstanding, may vote.
The agenda centers on governance and compensation: re-electing two Class II directors, approving an amended compensation policy, and authorizing new equity awards for directors, the chairman, CEO, and CTO. Proposals also seek higher annual fees for non-executive directors, a minimum NIS 3.5 per U.S. dollar exchange rate for converting the chairman’s pay, and re-appointment of Deloitte as auditor for 2026. The board unanimously recommends voting in favor of all proposals.
Polyrizon Ltd. reports clinical progress for its NASARIX™ (PL-14) program, signing agreements with two additional U.S. clinical sites and bringing the total to three major contracted centers for its upcoming trial. These sites are described as the largest and most strategically important in its planned multi-center study and are expected to provide the highest patient enrollment.
The trial will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis, with up to five U.S. sites expected to participate. NASARIX™ is an intranasal hydrogel intended to form a protective barrier in the nasal cavity to block airborne allergens. The study will follow international Good Clinical Practice standards and support the company’s broader regulatory strategy.
Polyrizon Ltd. reports that it has extended negotiations for its proposed acquisition of a 51% stake in Arrow Aviation Ltd. The companies signed a letter agreement effective June 3, 2026, extending the MOU exclusivity and Initial Negotiation Period to June 30, 2026, while keeping all other MOU terms unchanged.
The report also states that this update is incorporated by reference into Polyrizon’s registration statements on Form S-8 and Form F-3 filed with the SEC.
Polyrizon Ltd. reported that its Board of Directors appointed Ami Oren as a Class I director, effective May 14, 2026. Oren, age 51, has over 20 years of experience founding and operating consumer-facing businesses, including Hummus Ami and prior catering and culinary ventures.
The report states that this information is incorporated by reference into Polyrizon’s existing Registration Statements on Form S-8 (File Nos. 333-284410 and 333-288923) and Form F-3 (File No. 333-291368), meaning those securities registration documents now include this updated board composition detail.